For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...
Amber Implants, a Netherlands medtech developing next-generation implants for spinal injuries, named Vincent Gardès as CEO.
A new movement of people seeking connection and purpose forget they’re talking to AI and project their vulnerabilities onto ...
Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Given the importance of recursion in modern linguistics, there ought to be much to commend in Watumull et al.'s (2014) attempt to clarify what recursion is (or ought to be); I have trudged this very ...
Hosted on MSN
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results